Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02117050 · ClinicalTrials.gov registry record · Phase 4
RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
A Phase 4 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT02117050 is a Phase 4 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 1 participants.
The verdict
NCT02117050, a Phase 4 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment satisfaction in patients with relapsing forms of Multiple Sclerosis (MS) who are currently being treated with, but are considering discontinuing treatment with Tecfidera™.
Interventions
- DRUG Rebif®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02117050
The ClinicalTrials.gov registry entry for NCT02117050 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rebif® is the first listed.
NCT02117050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02117050 about?
NCT02117050 is a clinical study titled "RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate". This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment satisfaction in patients with relapsing forms of Multiple Sclerosis (MS) who are currently being treated with, but are considering discontinuing treatment with Tecfidera™.
What is the current status of trial NCT02117050?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2014-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02117050?
The interventions under investigation include: Rebif® (DRUG).
Who is sponsoring clinical trial NCT02117050?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.